Please assess the completion status of the following clinical trial:

Trial Title: MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of AML or high risk MDS.~* Elderly cohort (70 years of age or more): no prior chemotherapy treatment for AML/high risk MDS and not currently candidates for intensive chemotherapy.~* Relapsed/refractory cohort (18 years of age or more): relapsed or refractory to prior treatment.~* ECOG performance status of 0 or 1.~* Total bilirubin \< 1.5 x upper limit of normal (ULN).~* AST/SGOT and ALT/SGPT \< 2.5 x ULN.~* Serum creatinine \< 1.5 x ULN.~* Patients must read, understand, and sign a written informed consent form (ICF).~* Women of childbearing potential and male patients' female partners must use an acceptable method of contraception while on study, and for 3 months after study drug treatment.~Exclusion Criteria:~* Pregnant or lactating women.~* Patients with uncontrolled, intercurrent illness, active or uncontrolled infections, or a fever \> 38.5C (not due to tumor fever) on the day of scheduled dosing.~* Patients with serious illnesses or medical conditions, including laboratory results, which, in the investigator's opinion, would interfere with a patient's participation, or with the interpretation of the results.~* Patients treated with an investigational drug within 30 days prior to study initiation.~* Known hypersensitivity to HDAC inhibitors or to any of the components of MG-0103.~* Known HIV or active hepatitis B or C.~* Any condition that may affect the patient's ability to sign the ICF and undergo study procedures.~* Any conditions that will put the patient at undue risk or discomfort as a result of adherence to study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Elderly (≥65 years) untreated arm
- 2 (Type: EXPERIMENTAL): Relapsed/Refractory Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).